Special items: Ovarian Cancer and Us blog best viewed in Firefox

▼

Thursday, January 07, 2010

JCO Editorial: Biomarkers of Antiangiogenic Therapy: How Do We Move From Candidate Biomarkers to Valid Biomarkers?

"Thus, these candidate biomarkers should continue to be actively explored in trials of antiangiogenic agents in patients, to get closer to the goal of improving and individualizing cancer therapy."

1 comment:

  1. Greg PawelskiSaturday, March 5, 2011 at 10:16:00 AM EST

    AngioRx: Valid Biomarker of Antiangiogenic Therapy

    http://cancerfocus.org/forum/showthread.php?t=3372

    ReplyDelete

Your comments?

Note: Only a member of this blog may post a comment.